WSJ -- Johnson & Johnson's (JNJ) Cordis unit is facing a potential U.S. supply disruption for its Cypher heart stents because Abbott Laboratories (ABT) will soon stop supplying catheters most commonly used to install the tiny devices, Cordis confirmed Thursday.
